• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Eliem Therapeutics Inc

    5/7/24 6:01:49 PM ET
    $ELYM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELYM alert in real time by email
    SC 13G 1 eliem-sc13g_050724.htm SCHEDULE FILED TO REPORT ACQUISTION OF BENEFICIAL OWNERSHIP

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. __)*

      Eliem Therapeutics, Inc  
      (Name of Issuer)  
         
      Common Stock, par value $0.0001 per share  
      (Title of Class of Securities)  
         
      28658R 106  
      (CUSIP Number)  
         
      Michael Hirschberg, Esq.  
      Reitler Kailas & Rosenblatt LLP  
      885 Third Avenue, 20th Floor  
      New York, NY 10022  
         
      (Name, Address and Telephone Number of Person  
      Authorized to Receive Notices and Communications)  
         
      May 1, 2024  
      (Date of Event which Requires Filing of this Statement  

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 28658R 106   13G   Page 2 of 7 Pages

             
    1.  

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Affinity Healthcare Fund, LP (EIN 82-1629802)

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructios)

    (a) ☐

    (b) ☐

       
    3.   SEC USE ONLY
     
       
    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

     

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.

     

     

     

    SOLE VOTING POWER
    0 
      6.  

    SHARED VOTING POWER

    1,670,000 shares of Common Stock
     

      7.  

    SOLE DISPOSITIVE POWER
     0

     

      8.  

    SHARED DISPOSITIVE POWER

    1,670,000 shares of Common Stock
     

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,670,000 shares of Common Stock
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions) ☐
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.02%
       
    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

       

     

     

     

    CUSIP No. 28658R 106   13G   Page 3 of 7 Pages
             
    1.  

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Affinity Asset Advisors, LLC (EIN 82-1567490)

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a) ☐
    (b) ☐
       
    3.   SEC USE ONLY
     
       
    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

     

       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     0

      6.  

    SHARED VOTING POWER

    1,670,000 shares of Common Stock
     

      7.   SOLE DISPOSITIVE POWER
     0

      8.  

    SHARED DISPOSITIVE POWER

    1,670,000 shares of Common Stock 

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,670,000 shares of Common Stock
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions) ☐
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.02%
       
    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    IA

       

     

     

     

    CUSIP No. 28658R 106   13G   Page 4 of 7 Pages

    Item 1.

      (a)

    Name of Issuer:

        Eliem Therapeutics, Inc.
         
      (b) Address of Issuer’s Principal Executive Offices:
         
        PMB #117
        2801 Centerville Road 1st Floor
        Wilmington, DE 19808-1609

    Item 2.

      (a)

    Name of Persons Filing:

        Affinity Healthcare Fund, LP
        Affinity Asset Advisors, LLC
         
      (b)

    Address of Principal Business Office or, if None, Residence:

        767 Third Avenue, 15th Floor
        New York, NY 10017
         
      (c)

    Citizenship:

        Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC - Delaware
         
      (d)

    Title of Class of Securities:

        Common Stock, par value $0.0001 per share
         
      (e)

    CUSIP Number:

        28658R 106

     

     

     

    CUSIP No. 28658R 106   13G   Page 5 of 7 Pages

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) ☐

    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

     

     

    CUSIP No. 28658R 106   13G   Page 6 of 7 Pages

    Item 4. Ownership.

    Affinity Asset Advisors, LLC (the “Advisor”) is the investment manager of Affinity Healthcare Fund, LP (the “Fund”) and exercises investment discretion with regard to the securities reported herein. As of May 7, 2024, the Fund beneficially owned an aggregate of 1,670,000 shares of Common Stock of the Issuer, or 6.02% of the outstanding shares of Common Stock of the Issuer, and the Advisor may be deemed to be the beneficial owner of such 1,670,000 shares of Common Stock of the Issuer owned by the Fund by virtue of its position as investment manager of the Fund. The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of 1,670,000 shares of Common Stock of the Issuer.

    The percentage set forth in the preceding paragraph and in Row 11 of the cover page for each reporting person is based on 27,723,824 shares of Common Stock of the Issuer outstanding as of March 31, 2024 as set forth in the Issuer’s Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on April 29, 2024.

    Item 5. Ownership of Five Percent or Less of a Class.

    Not Applicable

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable 

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not Applicable

    Item 8. Identification and Classification of Members of the Group.

    Not Applicable 

    Item 9. Notice of Dissolution of Group.

    Not Applicable

    Item 10. Certification.

    By signing below, we certify that, to the best of our knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  

     

     

     

    CUSIP No. 28658R 106   13G   Page 7 of 7 Pages

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

        May 7, 2024
        Date
         
        Affinity Healthcare Fund, LP
         
        By: /s/ Michael Cho
        Signature
         
        AFFINITY ASSET ADVISORS, LLC
         
        By: /s/ Michael Cho
        Signature

     
    Get the next $ELYM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELYM

    DatePrice TargetRatingAnalyst
    9/7/2021$32.00Buy
    Guggenheim
    9/7/2021$35.00Buy
    Stifel
    9/7/2021$33.00Outperform
    SVB Leerink
    More analyst ratings

    $ELYM
    Financials

    Live finance-specific insights

    See more
    • Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

      Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE, United Kingdom, March 06, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter and year ended December 31, 2022. "We are excited to advance

      3/6/23 4:10:00 PM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

      Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in the first quarter of 2023 Cash runway expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported

      11/14/22 6:10:00 AM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

      Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022 Capital now expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Aug. 15, 2022 (GLOBE NEWSWIRE) --  Eliem Therapeutics, Inc. (NASDAQ:ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended June 30, 2022. "We continue to advance our pipeline targeting neuronal excitability disorders," said Bob Azelby, pres

      8/15/22 6:10:00 AM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELYM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Eliem Therapeutics Inc

      SC 13D/A - Eliem Therapeutics, Inc. (0001768446) (Subject)

      8/16/24 4:23:26 PM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Eliem Therapeutics Inc

      SC 13G/A - Eliem Therapeutics, Inc. (0001768446) (Subject)

      8/14/24 4:05:20 PM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Eliem Therapeutics Inc

      SC 13G - Eliem Therapeutics, Inc. (0001768446) (Subject)

      7/2/24 4:01:44 PM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELYM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Eliem Therapeutics with a new price target

      Guggenheim initiated coverage of Eliem Therapeutics with a rating of Buy and set a new price target of $32.00

      9/7/21 7:18:57 AM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Eliem Therapeutics with a new price target

      Stifel initiated coverage of Eliem Therapeutics with a rating of Buy and set a new price target of $35.00

      9/7/21 7:17:07 AM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on Eliem Therapeutics with a new price target

      SVB Leerink initiated coverage of Eliem Therapeutics with a rating of Outperform and set a new price target of $33.00

      9/7/21 6:28:45 AM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELYM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF ACCOUNTING OFFICER Pimblett Emily converted options into 5,000 shares and sold $9,741 worth of shares (1,191 units at $8.18), increasing direct ownership by 101% to 7,564 units (SEC Form 4)

      4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)

      9/20/24 9:53:19 PM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Kaplan Brett

      4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)

      8/26/24 5:47:35 PM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Kaplan Brett

      3 - Eliem Therapeutics, Inc. (0001768446) (Issuer)

      8/26/24 5:40:27 PM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELYM
    Leadership Updates

    Live Leadership Updates

    See more

    $ELYM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Eliem Therapeutics Reports Second Quarter Financial Results

      Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119), pipeline expansion strategy and anticipated milestones Cash and cash equivalents of approximately $220 million expected to fund operations into 2027, to enable the potential attainment of key clinical and development milestones for budoprutug SEATTLE and CAMBRIDGE, United Kingdom, Aug. 14, 2024 (GLOBE NEWSWIRE) --  Eliem Therapeutics, Inc. (NASDAQ:ELYM) ("Eliem" or the "Company"), today reported financial results for the quarter ended June 30, 2024 and provided a business

      8/14/24 6:05:00 AM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

      Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy Post-close cash and cash equivalents of $220 million expected to fund operations into 2027, to enable the potential attainment of key clinical and development milestones for TNT119 Announces the appointments of Dr. Aoife Brennan as President, Chief Executive Officer and Director, and Dr. Jan Hillson as Senior Clinical Advisor; Dr. Stephen Thomas, former Tenet CEO, appointed to Eliem's Board of Directors SEATTLE and CAMBRIDGE, United Kingdom, June 27, 2024 (GLOBE NEWSWIRE) -- Eliem Ther

      6/27/24 4:01:00 PM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

      Company to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123 Pausing clinical development of ETX-155 for Major Depressive Disorder (MDD) due to challenging capital environment Implementing corporate reorganization to extend cash runway into 2027 SEATTLE and CAMBRIDGE, United Kingdom, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM) ("Eliem" or the "Company"), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a strategic business update and an

      2/9/23 4:01:00 PM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ra Capital Management, L.P. was granted 5,259,872 shares and bought $49,952,817 worth of shares (13,008,546 units at $3.84) (SEC Form 4)

      4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)

      7/1/24 9:29:04 PM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELYM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

      Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM" effective October 3rd WELLESLEY, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) --  Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today that it will change its corporate name to Climb Bio, Inc. The new name and corporate brand reflect the Company's new mission to develop a pipeline focused on immune-mediated diseases, following its acquisition of Tenet Medicines, Inc. In conjunction with the corporate name change, the Company will begin trading under the new ticker symbol "CLYM" on the Nasdaq Global Mar

      10/2/24 9:00:23 AM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

      SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024. Stifel 2024 Virtual Immunology and Inflammation SummitDate: Wednesday, September 18, 2024Format: 1x1 meetings About Eliem Therapeutics, Inc.Eliem Therapeutics is focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, immune thrombocyto

      9/11/24 7:00:00 AM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eliem Therapeutics Announces Additions to its Leadership Team

      Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE, United Kingdom, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today the appointments of Brett Kaplan, M.D., as Chief Operating Officer, and Nishi Rampal, M.D., as Senior Vice President, Clinical Development. "I am delighted to announce the addition of Brett and Nishi to our executive team," said Dr. Aoife Brennan, CEO of Eliem Therapeutics. "Since completing the Tenet Medicines acquisition, we have worked diligently to build a best-in-class management team as we transition Eliem into a leading bio

      8/26/24 7:00:00 AM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELYM
    SEC Filings

    See more
    • SEC Form 8-K filed by Eliem Therapeutics Inc

      8-K - Climb Bio, Inc. (0001768446) (Filer)

      10/2/24 4:15:00 PM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Eliem Therapeutics Inc

      8-K - Eliem Therapeutics, Inc. (0001768446) (Filer)

      8/27/24 5:21:52 PM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Eliem Therapeutics Inc

      8-K - Eliem Therapeutics, Inc. (0001768446) (Filer)

      8/26/24 7:07:00 AM ET
      $ELYM
      Biotechnology: Pharmaceutical Preparations
      Health Care